Chimerix (NASDAQ:CMRX) appointed Dr. Allen Melemed as its CMO.
Dr. Melemed was most recently a distinguished medical fellow and senior director of North American regulatory affairs oncology at Eli Lilly (NYSE:LLY). He spent more than 20 years at the company, dedicated to the clinical development and approval of oncology medicines across a broad range of tumor types.
“We look forward to leveraging [Dr. Melemed’s] considerable clinical and regulatory experience as a distinguished pharmaceutical executive,” Mike Sherman, Chimerix’s CEO, said in a statement.
“His vast experience bringing oncology therapeutics through development and approval across multiple modalities will be invaluable as we initiate our dociparstat sodium Phase 3 trial in first-line acute myeloid leukemia, our ongoing Phase 2/3 trial to combat acute lung injury in COVID-19 patients, and finalize our rolling NDA for brincidofovir as a medical countermeasure for smallpox,” he added.
